Lincoln Pharmaceuticals Limited
Lincoln Pharmaceuticals Limited (LINCOLN) financial statements and selected valuation metrics from NSE/BSE exchange filings through 30 June 2026.
Healthcare›Healthcare›Pharmaceuticals & Biotechnology›Pharmaceuticals
lincolnpharma.com(opens the company website in a new tab)Key metrics
Price as of 2026-09-03
Sign in for full ratios and TTM. Learn about these metrics →
Share price
NSE closing price from historical market data.
Loading price history…
Statement tables · Consolidated
Switches quarterly, P&L, balance sheet, and cash flow. Key metrics and ratios stay on consolidated when available.
Amounts in ₹ Cr · NSE preferred when both exchanges report the same period · tap + to expand rows
Quarterly results
Quarterly · ₹ Cr · tap + rows to expand
| Metric | Sept 2023 | Dec 2023 | Mar 2024 | Jun 2024 | Sept 2024 | Dec 2024 | Mar 2025 | Jun 2025 | Sept 2025 | Dec 2025 | Mar 2026 | Jun 2026 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Sales | 156 Cr | 146 Cr | 142 Cr | 147 Cr | 161 Cr | 147 Cr | 168 Cr | 154 Cr | 163 Cr | 166 Cr | 187 Cr | 177 Cr |
| Operating expenses (approx.) | 125 Cr | 117 Cr | 124 Cr | 125 Cr | 133 Cr | 123 Cr | 141 Cr | 130 Cr | 138 Cr | 143 Cr | 162 Cr | 150 Cr |
| EBITDA | 31 Cr | 30 Cr | 18 Cr | 23 Cr | 28 Cr | 24 Cr | 27 Cr | 24 Cr | 25 Cr | 24 Cr | 25 Cr | 27 Cr |
| OPM % | 20.0% | 20.3% | 12.9% | 15.4% | 17.6% | 16.1% | 15.9% | 15.5% | 15.6% | 14.2% | 13.3% | 15.5% |
| Other income | 9 Cr | 11 Cr | 7 Cr | 10 Cr | 10 Cr | 9 Cr | -7 Cr | 15 Cr | 7 Cr | 15 Cr | -4 Cr | 24 Cr |
| Interest | 0.39 Cr | 0.15 Cr | 0.50 Cr | 0.44 Cr | 0.35 Cr | 0.73 Cr | 0.37 Cr | 0.21 Cr | 0.23 Cr | 0.30 Cr | 0.27 Cr | 0.26 Cr |
| Depreciation | 3 Cr | 3 Cr | 3 Cr | 3 Cr | 3 Cr | 3 Cr | 3 Cr | 3 Cr | 4 Cr | 4 Cr | 4 Cr | 4 Cr |
| Profit before tax | 37 Cr | 38 Cr | 22 Cr | 29 Cr | 35 Cr | 29 Cr | 16 Cr | 35 Cr | 29 Cr | 35 Cr | 17 Cr | 48 Cr |
| Tax % | 25.0% | 25.6% | 16.3% | 19.7% | 24.3% | 27.6% | 28.8% | 21.8% | 30.6% | 17.6% | 30.3% | 23.8% |
| Net profit | 28 Cr | 28 Cr | 19 Cr | 24 Cr | 26 Cr | 21 Cr | 12 Cr | 28 Cr | 20 Cr | 29 Cr | 12 Cr | 36 Cr |
| EPS (₹) | ₹13.81 | ₹14.00 | ₹9.28 | ₹11.82 | ₹13.15 | ₹10.37 | ₹5.78 | ₹13.82 | ₹9.98 | ₹14.28 | ₹5.81 | ₹18.09 |
Profit & loss (annual)
Annual · last column is TTM · ₹ Cr · tap + to expand
| Metric | Mar 2022 | Mar 2023 | Mar 2024 | Mar 2025 | Mar 2026 | TTM |
|---|---|---|---|---|---|---|
| Sales | 472 Cr | 510 Cr | 581 Cr | 623 Cr | 671 Cr | Sign in for TTM |
| Operating expenses (approx.) | 377 Cr | 421 Cr | 481 Cr | 522 Cr | 573 Cr | Sign in for TTM |
| EBITDA | 95 Cr | 89 Cr | 100 Cr | 101 Cr | 98 Cr | Sign in for TTM |
| OPM % | 20.2% | 17.5% | 17.2% | 16.3% | 14.6% | Sign in for TTM |
| Other income | 10 Cr | 22 Cr | 34 Cr | 22 Cr | 33 Cr | Sign in for TTM |
| Interest | 1 Cr | 2 Cr | 1 Cr | 2 Cr | 1 Cr | Sign in for TTM |
| Depreciation | 8 Cr | 9 Cr | 11 Cr | 13 Cr | 14 Cr | Sign in for TTM |
| Profit before tax | 96 Cr | 100 Cr | 122 Cr | 109 Cr | 116 Cr | Sign in for TTM |
| Tax % | 27.7% | 27.4% | 23.7% | 24.6% | 24.0% | Sign in for TTM |
| Net profit | 69 Cr | 73 Cr | 93 Cr | 82 Cr | 88 Cr | Sign in for TTM |
| EPS (₹) | ₹34.63 | ₹36.40 | ₹46.58 | ₹41.11 | ₹43.88 | Sign in for TTM |
| Dividend payout % | 4.3% | 4.1% | 3.2% | 4.4% | 4.1% | Sign in for TTM |
Trailing twelve months totals and margin rows
Balance sheet
Annual · ₹ Cr · tap + rows to expand
| Metric | Mar 2022 | Mar 2023 | Mar 2024 | Mar 2025 | Mar 2026 |
|---|---|---|---|---|---|
| Equity capital | 20 Cr | 20 Cr | 20 Cr | 20 Cr | 20 Cr |
| Reserves | 413 Cr | 482 Cr | 573 Cr | 652 Cr | 738 Cr |
| Borrowings | 2 Cr | 2 Cr | 1 Cr | — | 4 Cr |
| Other liabilities | 99 Cr | 83 Cr | 106 Cr | 125 Cr | 128 Cr |
| Total liabilities | 534 Cr | 587 Cr | 700 Cr | 797 Cr | 890 Cr |
| Fixed assets (net) | 131 Cr | 150 Cr | 179 Cr | 182 Cr | 190 Cr |
| CWIP | 16 Cr | 7 Cr | 3 Cr | 4 Cr | 5 Cr |
| Investments | 97 Cr | 91 Cr | 139 Cr | 174 Cr | 209 Cr |
| Loans & advances | 32 Cr | 23 Cr | 38 Cr | 35 Cr | 81 Cr |
| Inventories | 73 Cr | 70 Cr | 77 Cr | 79 Cr | 80 Cr |
| Trade receivables | 116 Cr | 136 Cr | 162 Cr | 166 Cr | 161 Cr |
| Cash & bank | 7 Cr | 5 Cr | 6 Cr | 13 Cr | 22 Cr |
| Other assets | 63 Cr | 105 Cr | 96 Cr | 144 Cr | 143 Cr |
| Total assets | 534 Cr | 587 Cr | 700 Cr | 797 Cr | 890 Cr |
Cash flows
Annual · ₹ Cr · tap + rows to expand · last column includes FCF
| Metric | Mar 2022 | Mar 2023 | Mar 2024 | Mar 2025 | Mar 2026 |
|---|---|---|---|---|---|
| Cash from operating activity | 76 Cr | 39 Cr | 63 Cr | 93 Cr | 106 Cr |
| Cash from investing | -78 Cr | -37 Cr | -57 Cr | -79 Cr | -98 Cr |
| Cash from financing | -3 Cr | -5 Cr | -5 Cr | -6 Cr | 0.16 Cr |
| Net cash flow | -5 Cr | -2 Cr | 0.70 Cr | 8 Cr | 8 Cr |
| Free cash flow (OCF − Capex) | 31 Cr | 25 Cr | 24 Cr | 74 Cr | 80 Cr |
Ratios
Ratios as reported or derived per annual period.
| Metric | Mar 2022 | Mar 2023 | Mar 2024 | Mar 2025 | Mar 2026 |
|---|---|---|---|---|---|
| ROCE % | 22.4% | 20.3% | 20.8% | 16.5% | 15.3% |
| ROE % | 16.0% | 0.0% | 0.0% | 0.0% | 0.0% |
| Debtor days | 89 | 97 | 102 | 97 | 88 |
| Inventory days | 167 | 144 | 140 | 134 | 122 |
| Days payable | 165 | 105 | 131 | 145 | 129 |
| Cash conversion cycle | 92 | 136 | 110 | 87 | 80 |
| Debt / equity | 0.0047 | 0.0040 | 0.0018 | — | 0.0058 |
| Current ratio | 3.90 | 5.08 | 4.84 | 4.71 | 5.25 |
| Net debt / EBITDA | -0.05 | -0.03 | -0.05 | -0.13 | -0.18 |
Compare with peers
Loading peers…